Collagenase: Future Perspectives
Collagenase Clostridium histolyticum (CCH) was introduced in 2009  and was approved by the FDA for use in the United States under the name Xiaflex® for the treatment among adults with a palpable Dupuytren’s cord, on February 2, 2010.
- 2.Gelbard M, Goldstein I, Hellström WJ, McMahon CH, Smith T, Tursi J, Jones N, Kaufman GJ, Carson CC. Clinical efficacy, safety and tolerability of collagenase clostridium histolyticum for the treatment of Peyronie disease in 2 large double-blind, randomized, placebo controlled phase 3 studies. J Urol. 2013;190(1):199–207.CrossRefPubMedGoogle Scholar
- 12.Bulgen DY, Binder A, Hazeman BL, et al. Immunological studies in frozen shoulder. J Rheumatol. 1992;9(6):893–8.Google Scholar
- 15.Fischer S, Hirche C, Diehm Y, Nuutila K, Kiefer J, Gazyakan E, Bueno EM, Kremer T, Kneser U, Pomahac B. Efficacy and safety of the collagenase of the Bacterium Clostridium histolyticum for the treatment of capsular contracture after silicone implants: ex-vivo study on human tissue. PLoS One. 2016;11(5):e0156428.CrossRefPubMedPubMedCentralGoogle Scholar
- 18.Auxilium Pharmaceuticals, Inc. Press Release. “Auxilium Pharmaceuticals, Inc. announces positive data from phase 2a study of CCH in patients with cellulite.” August 21, 2014.Google Scholar
- 19.BioSpecifics Technologies Corp. Press Release. BioSpecifics Technologies Corp. announced positive, highly statistically significant results from a Phase 2b study of CCH for the treatment of cellulite, or edematous fibrosclerotic panniculopathy. Lynbrook, NY, November 17, 2016.Google Scholar
© Springer International Publishing AG, part of Springer Nature 2018